RESUMEN
BACKGROUND: Multifocal choroiditis (MFC) is an inflammatory condition, occasionally associated with choroidal neovascularization (CNV). Bevacizumab (Avastin) and ranibizumab (Lucentis) are therapies that target vascular endothelial growth factor. Bevacizumab and ranibizumab have been used successfully to treat CNV in age-related and myopic macular degeneration. PURPOSE: : To describe the treatment of MFC-associated CNV with intravitreal bevacizumab and/or ranibizumab. DESIGN: Retrospective interventional case series. PARTICIPANTS: Six eyes of five patients with MFC-associated CNV were treated with intravitreal bevacizumab and/or ranibizumab. MAIN OUTCOME MEASURES: Visual acuity at 1, 3, and 6 months after the initial injection. RESULTS: Previous therapies (number of eyes treated) included sub-Tenon's corticosteroids (2), intravitreal corticosteroids (1), photodynamic therapy (1), and thermal laser (1). The mean number (range) of antivascular endothelial growth factor injections per eye was 2.3 (1-6). The mean duration (range) of follow-up per patient was 41.5 (25-69) weeks. Five of six eyes improved to 20/30 acuity or better at 6 months. One eye suffered a subfoveal rip of the retinal pigment epithelium with 20/400 acuity. There was a qualitative decrease in clinical and angiographic evidence of CNV. CONCLUSIONS: Bevacizumab and ranibizumab were effective at improving visual acuity over 6 months in a small series of patients with MFC-associated CNV. Tears of the retinal pigment epithelium may occur after intravitreal antivascular endothelial growth factor therapy in MFC-associated CNV.
Asunto(s)
Inhibidores de la Angiogénesis/uso terapéutico , Anticuerpos Monoclonales/uso terapéutico , Neovascularización Coroidal/tratamiento farmacológico , Coroiditis/tratamiento farmacológico , Adulto , Anticuerpos Monoclonales Humanizados , Bevacizumab , Neovascularización Coroidal/etiología , Coroiditis/complicaciones , Quimioterapia Combinada , Femenino , Angiografía con Fluoresceína , Estudios de Seguimiento , Humanos , Inyecciones , Masculino , Persona de Mediana Edad , Ranibizumab , Estudios Retrospectivos , Factor A de Crecimiento Endotelial Vascular/antagonistas & inhibidores , Agudeza Visual , Cuerpo VítreoRESUMEN
STUDY OBJECTIVE: We determine the prevalence of nontherapeutic and coagulopathic international normalized ratios (INRs) among patients receiving warfarin and presenting to an emergency department (ED). As a secondary goal, we aim to determine whether a simple decision aid composed of physical examination and historical features could be predictive of INR greater than 5. METHODS: This was a prospective, observational study at 2 associated urban academic centers from February 2003 through May 2004, using a convenience sample of patients identified by direct questioning and contemporaneous medical record review in the ED as receiving long-term warfarin therapy. Inclusion criteria were warfarin therapy and self-reported compliance. Patients were enrolled by trained researchers. The primary outcome measure was the percentage of patients within appropriate therapeutic range for their condition according to accepted national guidelines. Descriptive statistics were used, and multivariate regression analysis was performed to identify associations. RESULTS: One thousand nineteen patients were enrolled. INR values were obtained in 77% (782/1019) of patients. Of these patients, 72% (95% confidence interval 67% to 76%) were outside the desired range. Values were less than 2 in 43% of patients and greater than 3 in 29% of patients. INR greater than 5 was present in 11% (86/782) of patients, and 40% (34/86) of these patients exhibited gross bleeding. Emergency therapy was administered in 12% (96/782) of patients: fresh frozen plasma in 7% of patients, heparin in 5% of patients. Intracranial hemorrhage was found in 12 patients, 5 with INR greater than 3. Ischemic stroke or venous thromboembolism occurred in 51 patients known to be receiving warfarin specifically for prevention of the event that occurred. Of these patients, 49% (25/51) had INR less than 2. Regression analysis indicated no sensitive or specific constellation of features, though 2 factors were associated with INR greater than 5: gross hemorrhage (P=.006) and increasing duration of therapy (P=.047). CONCLUSION: The prevalence of undesirable INR in the ED is higher than in warfarin populations previously studied, and a significant number of nontherapeutic levels were associated with thromboembolism, stroke, or hemorrhage. Given the prevalence and established danger of subtherapeutic and supratherapeutic levels, a low threshold should be maintained for testing and addressing INR levels in patients receiving warfarin in the ED.
Asunto(s)
Anticoagulantes/uso terapéutico , Servicio de Urgencia en Hospital , Relación Normalizada Internacional/estadística & datos numéricos , Warfarina/uso terapéutico , Centros Médicos Académicos , Anciano , Anciano de 80 o más Años , Anticoagulantes/efectos adversos , Técnicas de Apoyo para la Decisión , Servicio de Urgencia en Hospital/normas , Servicio de Urgencia en Hospital/estadística & datos numéricos , Femenino , Humanos , Relación Normalizada Internacional/normas , Masculino , Auditoría Médica , Anamnesis , Persona de Mediana Edad , Análisis Multivariante , Cooperación del Paciente , Examen Físico , Estudios Prospectivos , Warfarina/efectos adversosRESUMEN
OBJECTIVE: To analyze the frequency of major age-related macular degeneration (AMD)-associated alleles in patients with multifocal choroiditis (MFC). METHODS: A cohort of 48 patients with MFC was compared with previously characterized cohorts of patients with advanced AMD (368 samples) and matched unaffected controls (368 samples). Allele and genotype frequencies of single nucleotide polymorphisms for the following AMD-associated alleles were evaluated: risk alleles in complement factor H (CFH) gene (Y402H and IVS14) and LOC387715/HTRA1 gene on 10q26 (A69S) and protective alleles in CFH (IVS1, IVS6, and delCFHR1-3) and complement factor B loci (H9L and R32Q). RESULTS: Frequencies of all major AMD-associated alleles in the CFH locus indicate a strong, statistically significant association of CFH gene single nucleotide polymorphisms and MFC. However, the same analysis for the single nucleotide polymorphisms in complement factor B and 10q26 loci matched the results in the control group. CONCLUSIONS: Like AMD, the MFC phenotype is strongly associated with the major alleles/haplotypes in the CFH locus. Clinical Relevance We report compelling evidence of a strong association between CFH polymorphisms and MFC, which contributes to the understanding of MFC pathogenesis and suggests new potential therapeutic targets.
Asunto(s)
Alelos , Coroiditis/genética , Degeneración Macular/genética , Anciano , Factor B del Complemento/genética , Factor H de Complemento/genética , Femenino , Frecuencia de los Genes , Genotipo , Humanos , Masculino , Persona de Mediana Edad , Reacción en Cadena de la Polimerasa , Polimorfismo de Longitud del Fragmento de Restricción , Polimorfismo de Nucleótido Simple , Proteínas/genéticaRESUMEN
OBJECTIVE: Endotracheal intubation by emergency medical services (EMS) is well established. Esophageal misplacement is a catastrophic complication that has until recently been studied by using methods that have called into question the accuracy of the reported data. The purpose of our study was to determine the incidence of unrecognized endotracheal tube misplacement, reasons for deferred intubations in the field, and to report outcomes in those patients with unrecognized misplacement. METHODS: This was a prospective observational study with a consecutive sample. All arriving with an endotracheal tube or in whom endotracheal intubation was performed within 10 minutes of arrival were included, and a physician immediately determined placement. Hospital records were reviewed to determine outcome of those patients in whom the tube was misplaced. Unrecognized esophageal misplacement triggered communication to the medical director of the transporting agency. RESULTS: During the enrollment period, 192 patients were evaluated. Overall, 132 of 192 (69%) were intubated in the prehospital environment, and 60 were intubated within 10 minutes of arrival in the emergency department. Among prehospital intubation attempts, 12 of 132 (9%; 95 CI 5.3-15.2), 11 esophageal, and 1 hypopharyngeal were misplaced. Right mainstem intubation occurred in an additional 20 of 132 (15%; 95 CI 10.0-22.3). Among patients arriving with unrecognized esophageal misplacement of the endotracheal tube, one patient survived to hospital discharge. CONCLUSION: The rate of esophageal misplacement of endotracheal tubes in the prehospital environment in our urban setting and the poor clinical course of patients with unrecognized misplacement is consistent with previous reports, suggesting that the benefit of prehospital airway management does not clearly supercede the potential risks.